SUBSCRIBE
SUBSCRIBE

Kivu Bioscience

NEWS
NextGen
BioSpace’s NextGen Class of 2026 Attracts Big Bucks From Tight Wallets
From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged during a tough fundraising environment in 2025. Check out the 15 battle-tested companies that caught our eye.
January 7, 2026
 · 
2 min read
 · 
Annalee Armstrong
IN THE PRESS
Press Releases
Kivu Bioscience Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical Officer
October 28, 2025
 · 
2 min read
Press Releases
Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025
October 21, 2025
 · 
3 min read
Press Releases
Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107
June 2, 2025
 · 
3 min read
Press Releases
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
October 28, 2024
 · 
4 min read
AWARDS
  • NextGen Class of 2026 Badge
JOBS